Blog
RSS FeedPosted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 24 Feb 2021
NICE terminates appraisal of Novartis medicine
24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal ...
Posted by Michael Wonder on 17 Feb 2021
Lupin responds to NICE Appraisal Consultation Document on NaMuscla (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders
16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) ...
Posted by Michael Wonder on 17 Feb 2021
bluebird bio ‘baffled’ after NICE rejects beta thalassaemia gene therapy
16 February 2021 - It’s back to the drawing board for bluebird bio and its discussions with NICE, which has ...
Posted by Michael Wonder on 15 Feb 2021
NICE rejects Lilly’s Verzenios for advanced breast cancer
15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of ...
Posted by Michael Wonder on 15 Feb 2021
bluebird bio’s beta thalassaemia gene therapy rejected by NICE
12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s ...
Posted by Michael Wonder on 14 Feb 2021
Skin cancer drug recommended for routine NHS use
12 February 2021 - An appeal period has now opened until 26 February 2021. ...
Posted by Michael Wonder on 14 Feb 2021
Does NICE influence the adoption and uptake of generics in the UK?
14 February 2021 - The aim of this paper is to examine generic competition in the UK, with a special focus ...
Posted by Michael Wonder on 07 Feb 2021
Modifying NICE’s approach to equity weighting
7 February 2021 - The UK’s NICE recently launched a consultation on the methods it uses to evaluate new health technologies, ...
Posted by Michael Wonder on 07 Feb 2021
NICE’s discounting review: clear thinking on rational revision meets obstacle of industrial interests
7 February 2021 - NICE recently published a review of discounting practice and theory as part of a consultation on ...
Posted by Michael Wonder on 04 Feb 2021
NICE’s processes of technology evaluation - presenting a case for change
4 February 2021 - NICE has today launched a public consultation on proposals for changes to the processes it uses to ...
Posted by Michael Wonder on 04 Feb 2021
Thousands of lung cancer patients to benefit from life extending treatment
4 February 2021 - A potentially life extending treatment for some people with non-squamous, non-small-cell lung cancer will now be available ...
Posted by Michael Wonder on 03 Feb 2021
NICE green light for GSK's Nucala
3 February 2021 - GlaxoSmithKline's Nucala (mepolizumab) will be funded on the NHS in England and Wales for treating patients ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 27 Jan 2021
NICE publishes final guidance on new use for Lonsurf
27 January 2021 - NICE has completed its review of trifluridine with tipiracil hydrochloride for the treatment of patients with ...